Synapse

← Charles M. Perou

Papers by Charles M. Perou

Page 2 · newest first

  1. HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II TrialClinical Cancer Research · 2024
  2. Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancerScientific Reports · 2024
  3. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancerFuture Oncology · 2024
  4. Visual Intratumor Heterogeneity and Breast Tumor ProgressionCancers · 2024
  5. Defining the Regulatory Logic of Breast Cancer Using Single-Cell Epigenetic and Transcriptome Profiling2024
  6. Combination of polymeric micelle formulation of TGFβ receptor inhibitors and paclitaxel produces consistent response across different mouse models of Triple‐negative breast cancerBioengineering & Translational Medicine · 2024
  7. Data from The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer2024
  8. Supplementary Figure S1 from The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer2024
  9. Supplementary Figure S4 from The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer2024
  10. Supplementary Figure S3 from The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer2024
  11. Supplementary Figure S1 from The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer2024
  12. Supplementary Figure S2 from The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer2024
  13. Supplementary Figure S4 from The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer2024
  14. Supplementary Figure S2 from The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer2024
  15. Supplementary Figure S3 from The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer2024
  16. The immunomodulatory impacts of endocrine therapy on host immunity in early-stage hormone receptor positive, HER2 negative breast cancer.Journal of Clinical Oncology · 2024
  17. Associations of predictive biomarkers, MHC-I and MHC-II, with clinical and molecular features in a diverse breast cancer cohort.Journal of Clinical Oncology · 2024
  18. RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026).Journal of Clinical Oncology · 2024
  19. Receiver operating characteristic curves and confidence bands for support vector machines2024
  20. Abstract PO4-19-05: OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy (Alliance A012103)Cancer Research · 2024
  21. Abstract PO2-15-06: ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2-) advanced breast cancer following endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trialCancer Research · 2024
  22. Abstract PO5-01-09: Exploring cellular heterogeneity of localised breast cancersCancer Research · 2024
  23. Abstract PO1-08-12: Genomic Characterization of the Carolina Breast Cancer StudyCancer Research · 2024
  24. Abstract PO4-06-04: Understanding metastasis mixed-treatment responses through genomic analysesCancer Research · 2024
  25. Abstract PO3-05-06: Targeting PAM50 HER2-Enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer: results of the SOLTI-1502 ARIANNA trialCancer Research · 2024
  26. Abstract PO1-15-10: Lower pre-treatment B-cell gene expression signatures correspond with improved overall survival with palbociclib + endocrine therapy in HR+/HER2- metastatic breast cancer: a biomarker analysis from the GEICAM/2013-02 PEARL trialCancer Research · 2024
  27. Abstract PO2-15-08: Exploring Essential Immune Genes Linked to Pathological Complete Response and Survival in Early-Stage Triple-Negative Breast Cancer (TNBC) after Chemotherapy TreatmentCancer Research · 2024
  28. Abstract PO2-15-07: HER2DX genomic assay in triple-negative breast cancer (TNBC) patients treated with 12-weeks of neoadjuvant chemotherapy: a correlative analysis from WSG-ADAPT-TN phase II trialCancer Research · 2024
  29. Abstract PO3-16-03: Investigating HER2DX genomic assay concordance within HER2-positive breast cancerCancer Research · 2024
  30. Abstract PO2-01-06: Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in HER2+ early-breast cancer (EBC)Cancer Research · 2024
  31. 1MO HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancerESMO Open · 2024
  32. Supplementary Data from Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy2024
  33. Data from Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy2024
  34. Supplementary Data from Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy2024
  35. Abstract LB253: Crafted experiments to evaluate feature selection methods for single cell RNA-seq dataCancer Research · 2024
  36. The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast CancerClinical Cancer Research · 2024
  37. Research autopsy programmes in oncology: shared experience from 14 centres across the worldThe Journal of Pathology · 2024
  38. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast CancerJAMA Oncology · 2024
  39. Generative Adversarial Networks Accurately Reconstruct Pan-Cancer Histology from Pathologic, Genomic, and Radiographic Latent Features2024
  40. Abstract 2542: Real-world validation of the PurIST classifier demonstrates enhanced therapy selection for pancreatic ductal adenocarcinoma (PDAC) patientsCancer Research · 2024
  41. Abstract 1750: Decoding breast cancer: Unraveling subtype and model differences through multi-model single-cell RNA sequencing data integrationCancer Research · 2024
  42. Abstract 5213: Evaluation of HER2DX risk-score in residual disease (RD) from HER2-positive (HER2+) early breast cancer (EBC) patients (pts) following neoadjuvant trastuzumab and pertuzumab (HP)-based therapy: An exploratory analysis from the PHERGain trialCancer Research · 2024
  43. BIRC5 expression by race, age and clinical factors in breast cancer patientsBreast Cancer Research · 2024
  44. Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy2024
  45. Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapies2024
  46. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapynpj Breast Cancer · 2024
  47. A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studiesEBioMedicine · 2024
  48. Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancerESMO Open · 2024
  49. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)ESMO Open · 2024
  50. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their CombinationJAMA Oncology · 2024